SK Bioscience Q1 2026: CDMO-driven revenue growth, narrowing operating loss, no shareholder returns

Q1 2026 consolidated revenue KRW 168.6B, quarterly growth vs FY2025 KRW 651.4B; CDMO segment contributed 75.8%
Operating loss KRW 44.5B (narrowed from FY2025 loss of KRW 123.5B), net loss KRW 36.2B
R&D expenditure KRW 59.6B (35.4% of revenue), continued investment in pipeline and platforms
CDMO order backlog KRW 827.9B as of March 31, 2026, securing future revenue
Key pipeline: Sanofi co-development 21-valent pneumococcal vaccine global phase 3 ongoing; CEPI co-development mRNA vaccines
No dividend or share buyback; company prioritizes reinvestment
Lawsuits: minor claims from KDCA and Andong city; not material
Debt ratio 32% (debt KRW 968.3B, equity KRW 2,023.6B), stable financial structure